NASDAQ:ACRSAclaris Therapeutics Stock Price, Forecast & News

Aclaris Therapeutics' stock was trading at $1.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ACRS stock has increased by 37.7% and is now trading at $1.46. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aclaris Therapeutics.

Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Aclaris Therapeutics.

Aclaris Therapeutics Inc (NASDAQ:ACRS) posted its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by $0.38. The biotechnology company had revenue of $1.41 million for the quarter, compared to analyst estimates of $1.27 million. Aclaris Therapeutics had a negative return on equity of 99.67% and a negative net margin of 1,490.64%. View Aclaris Therapeutics' earnings history.

4 analysts have issued 12 month price targets for Aclaris Therapeutics' stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Aclaris Therapeutics' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 242.5% from the stock's current price. View analysts' price targets for Aclaris Therapeutics.

Media headlines about ACRS stock have trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aclaris Therapeutics earned a media sentiment score of -4.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutAclaris Therapeutics.

Aclaris Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 2,110,000 shares, a decrease of 12.8% from the April 30th total of 2,420,000 shares. Based on an average daily volume of 406,800 shares, the days-to-cover ratio is presently 5.2 days. Currently, 6.6% of the company's shares are short sold. View Aclaris Therapeutics' Current Options Chain.

Some companies that are related to Aclaris Therapeutics include LifeVantage (LFVN), Obseva (OBSV), Northwest Biotherapeutics (NWBO), OptiNose (OPTN), NuCana (NCNA), IDEAYA Biosciences (IDYA), Gemphire Therapeutics (GEMP), Lexicon Pharmaceuticals (LXRX), Aravive (ARAV), IVERIC bio (ISEE), Chimerix (CMRX), TAIWAN LIPOSOME/S (TLC), Paratek Pharmaceuticals (PRTK), Kalvista Pharmaceuticals (KALV) and vTv Therapeutics (VTVT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Abeona Therapeutics (ABEO), Anavex Life Sciences (AVXL), Cidara Therapeutics (CDTX), Crispr Therapeutics (CRSP), Amicus Therapeutics (FOLD), Nabriva Therapeutics (NBRV) and Progenics Pharmaceuticals (PGNX).

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Aclaris Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.28%), Vivo Capital LLC (3.93%), State Street Corp (1.59%), Telemetry Investments L.L.C. (1.20%), JPMorgan Chase & Co. (0.43%) and WINTON GROUP Ltd (0.28%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, James E Flynn, Kamil Ali-Jackson and Stephen A Tullman. View institutional ownership trends for Aclaris Therapeutics.

ACRS stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, State Street Corp, JPMorgan Chase & Co., Two Sigma Advisers LP, Alambic Investment Management L.P., and BlackRock Inc.. View insider buying and selling activity for Aclaris Therapeutics.

ACRS stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Invesco Ltd., Telemetry Investments L.L.C., Wells Fargo & Company MN, HighTower Advisors LLC, and Nuveen Asset Management LLC. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, and Stephen A Tullman. View insider buying and selling activity for Aclaris Therapeutics.

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ACRS stock can currently be purchased for approximately $1.46.

Aclaris Therapeutics has a market capitalization of $61.13 million and generates $4.23 million in revenue each year. The biotechnology company earns $-161,350,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.

The official website for Aclaris Therapeutics is www.aclaristx.com.

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]